Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Jing-Lin Zhao"'
Autor:
Zheng Yin, Zhi-Fan Li, Wen-Jia Zhang, Shuang Zhang, Yong-Gang Sui, Yan-Lu Xu, Hai-Tao Zhang, Xiao-Ning Liu, Hong Qiu, Jing-Lin Zhao, Jian-Jun Li, Ke-Fei Dou, Jie Qian, Yong-Jian Wu, Na-Qiong Wu
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e22222- (2023)
Background: For the patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) for at least 1 year is recommended in the guidelines to minimize the risk of stent thrombosis. Persi
Externí odkaz:
https://doaj.org/article/e60d00af4d0f417db20d61bcc23279d9
Publikováno v:
In Life Sciences 1 March 2016 148:9-16
Autor:
Wei-Jian Mei, Xiao-Zhong Wang, Yun-Feng Li, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Xuan Zhang, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Pei-Rong Ding
Publikováno v:
Annals of surgery.
To compare neoadjuvant chemotherapy (nCT) with CAPOX alone versus neoadjuvant chemoradiotherapy (nCRT) with capecitabine in locally advanced rectal cancer (LARC) with uninvolved mesorectal fascia (MRF).nCRT is associated with higher surgical complica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a7e827c2e04a08a10c3087b1e38fd0
https://pubmed.ncbi.nlm.nih.gov/36538627
https://pubmed.ncbi.nlm.nih.gov/36538627
Publikováno v:
EURASIA Journal of Mathematics, Science and Technology Education. 13
Tourism has become a pillar industry in developing provincial economy, and the high requirement is put forward on ecological protection, supporting infrastructure, etc. In this paper, China’s 31 provinces are studied by establishing a comprehensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21da3207f8b77ef742bd735f689aac98
https://doi.org/10.12973/ejmste/77930
https://doi.org/10.12973/ejmste/77930
Publikováno v:
Cardiovascular Therapeutics. 31:60-64
SUMMARY Introduction: Metformin is one of the most commonly prescribed antihyperglycemic agents for the treatment of type 2 diabetes. However, little is known about the effect of metformin on no-reflow in diabetic patients. Aim: In this study, we inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e161764376b38f1f6dd6e1a63067834
https://doi.org/10.1111/j.1755-5922.2011.00294.x
https://doi.org/10.1111/j.1755-5922.2011.00294.x
Publikováno v:
American Journal of Cardiovascular Drugs. 9:81-89
An association between admission plasma glucose levels and an increased risk of no-reflow has been well documented. Although HMG-CoA reductase inhibitor (statin) therapy can reduce no-reflow, little is known about its effect on no-reflow in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17d9659e1b1445b7ba35171a645409f3
https://doi.org/10.1007/bf03256579
https://doi.org/10.1007/bf03256579
Publikováno v:
Acta Cardiologica. 63:355-359
UNLABELLED It has been verified that adenosine can attenuate myocardial no-reflow. However, the effects of adenosine on adenosine triphosphate-sensitive K+ (KATP) channel and endothelin-1 (ET-1) are unknown. METHODS Forty mini-swines were randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae7d063a0da5fa155fd144ece6ce9bf
https://doi.org/10.2143/ac.63.3.1020313
https://doi.org/10.2143/ac.63.3.1020313
Publikováno v:
Scientia Pharmaceutica
Volume 76
Issue 2
Pages 171-184
Volume 76
Issue 2
Pages 171-184
It has been verified that glycoprotein IIb/IIIa inhibitor tirofiban can attenuate myocardial no-reflow. Myocardial no-reflow has been associated with alterations in endothelial junctions. In addition, ET-1 is an important mechanism for myocardial no-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac8fa799728db7b5de43802a22904195
https://doi.org/10.3797/scipharm.0803-21
https://doi.org/10.3797/scipharm.0803-21
Autor:
Yu-Hua Sun, Yue-Jin Yang, Yuan‐Hui Zhang, Jing-lin Zhao, Wei-Dong Pei, Run-Lin Gao, Ji‐Lin Chen
Publikováno v:
Clinical Cardiology. 30:130-134
Background In animal models, pretreatment with angiotensin-converting enzyme inhibitor (ACEI) can reduce no-reflow. In the present study, we investigated whether pretreatment with ACEI may prevent no-reflow in patients who underwent primary coronary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab06aaac05ae3f23f6f4abc0b2f6633
https://doi.org/10.1002/clc.20060
https://doi.org/10.1002/clc.20060
Autor:
Chen Jin, Kang Qi, Shi-Jie You, Yuejin Yang, Hehe Cui, Lujin Li, Lian Duan, Yang Wang, Hai-tao Zhang, Yu-tong Cheng, Qingshan Zheng, Sheng Kang, Fenghuan Hu, Jing-lin Zhao, Xiangdong Li
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119846 (2015)
PLoS ONE
PLoS ONE
Objective Tongxinluo (TXL) has been shown to decrease myocardial necrosis after ischemia/reperfusion (I/R) by simulating ischemia preconditioning (IPC). However, the core mechanism of TXL remains unclear. This study was designed to investigate the ke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f062dd7a35dc1ecb53be20ba93062c3c
http://europepmc.org/articles/PMC4363146?pdf=render
http://europepmc.org/articles/PMC4363146?pdf=render